Dacarbazine
- Generic Name
- Dacarbazine
- Drug Type
- Small Molecule
- Chemical Formula
- C6H10N6O
- CAS Number
- 4342-03-4
- Unique Ingredient Identifier
- 7GR28W0FJI
- Background
An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma.
- Indication
For the treatment of metastatic malignant melanoma. In addition, dacarbazine is also indicated for Hodgkin's disease as a secondary-line therapy when used in combination with other antineoplastic agents.
- Associated Conditions
- Advanced Pancreatic Neuroendocrine Tumors (pNET), Advanced Soft Tissue Sarcoma, Hodgkin's Lymphoma, Metastatic Melanoma, Pheochromocytoma, Advanced Medullary thyroid cancer
Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
- Conditions
- Advanced MelanomaUntreated Patients
- Interventions
- First Posted Date
- 2008-12-23
- Last Posted Date
- 2009-12-08
- Lead Sponsor
- Simcere Pharmaceutical Co., Ltd
- Target Recruit Count
- 140
- Registration Number
- NCT00813449
- Locations
- 🇨🇳
Beijing tumor hospital, Beijing, Beijing, China
Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma
- First Posted Date
- 2008-12-05
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 80
- Registration Number
- NCT00802880
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 72
- Registration Number
- NCT00796991
- Locations
- 🇺🇸
The Angeles Clinic & Research Inst., Los Angeles, California, United States
🇺🇸H Lee Moffit Cancer Cnt And Res Inst, Tampa, Florida, United States
🇺🇸Blumenthal Cancer Center, Carolinas Medical Center, Charlotte, North Carolina, United States
Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2008-10-24
- Last Posted Date
- 2008-10-24
- Lead Sponsor
- University of Wuerzburg
- Target Recruit Count
- 360
- Registration Number
- NCT00779714
- Locations
- 🇩🇪
Dept of Dermatology, University of Berlin Charite, Berlin, Germany
🇩🇪Dept of Dermatology, University of Aachen, Aachen, Germany
🇩🇪Dept of Dermatology, University of Jena, Jena, Germany
Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: bleomycin sulfateBiological: filgrastimBiological: pegfilgrastim
- First Posted Date
- 2008-05-15
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University College, London
- Target Recruit Count
- 1202
- Registration Number
- NCT00678327
- Locations
- 🇬🇧
Southampton General Hospital, Southampton, England, United Kingdom
Combination Chemotherapy With or Without Rituximab in Treating Participants With Stage III-IV Classic Hodgkin Lymphoma
- Conditions
- Classic Hodgkin LymphomaLugano Classification Stage IV Hodgkin Lymphoma AJCC v8Lugano Classification Stage III Hodgkin Lymphoma AJCC v8
- Interventions
- Biological: Rituximab
- First Posted Date
- 2008-04-09
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 58
- Registration Number
- NCT00654732
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
PTK/ZK in Disseminated Malignant Melanoma
- First Posted Date
- 2008-02-14
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- Michael Weichenthal
- Target Recruit Count
- 9
- Registration Number
- NCT00615160
- Locations
- 🇩🇪
Dpt. of Dermatology, University of Frankfurt, Frankfurt/Main, Germany
🇩🇪Dpt. of Dermatology, University of Cologne, Koeln, Germany
🇩🇪Dpt. of Dermatology; UK-SH Campus Kiel, Germany, Kiel, Germany
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
- Conditions
- Breast NeoplasmsBreast CancerColon CancerColonic CancerKidney CancerColon NeoplasmsLung CancerMelanoma
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT00600496
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma
- Conditions
- Parathyroid CarcinomaSoft Tissue SarcomaSmall Cell Carcinoma of the LungCarcinoid TumorsMelanoma
- Interventions
- First Posted Date
- 2007-12-24
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Virginia Commonwealth University
- Target Recruit Count
- 17
- Registration Number
- NCT00580320
- Locations
- 🇺🇸
Massey Cancer Center/Virginia Commonwealth University, Richmond, Virginia, United States
🇺🇸Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States
A Phase I, Randomized, Open-label, Cross-over, Pharmacokinetic Study of Genasense With and Without Dacarbazine
- Conditions
- Advanced Melanoma
- Interventions
- Drug: Genasense® (G3139, oblimersen sodium)Drug: Genasense followed by DTIC; then DTIC alone
- First Posted Date
- 2007-10-12
- Last Posted Date
- 2012-03-13
- Lead Sponsor
- Genta Incorporated
- Registration Number
- NCT00542893
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.